Anzeige
Mehr »
Samstag, 11.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
10.10.25 | 18:17
117,10 Euro
+0,77 % +0,90
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
115,70116,6010.10.
115,80116,5010.10.

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
IPSEN Aktie jetzt für 0€ handeln
DiIpsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 20251
DiIpsen Pharma: Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital1
30.09.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 20251
26.09.With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen7
26.09.Ipsen's tumour treatment receives MHRA marketing authorisation1
23.09.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 20259
22.09.Ipsen Reports Positive Phase II Data For IPN10200 In Glabellar Lines, Shows Long-Lasting Efficacy334PARIS (dpa-AFX) - Ipsen (IPSEY) announced first aesthetic data for glabellar lines from Stage 1 of its multi-stage, ongoing Phase II LANTIC trial evaluating the internally developed IPN10200....
► Artikel lesen
22.09.Ipsen: Positive Phase-II-Studiendaten für Ästhetik-Präparat IPN102003
22.09.Ipsen's IPN10200 shows promising results in Phase II aesthetics trial3
22.09.Ipsen Pharma: Ipsen's LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III378IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and...
► Artikel lesen
19.09.Ipsen Secures Japanese Approval For Bylvay In Treating Pruritus448PARIS (dpa-AFX) - Ipsen (IPSEY), Friday announced that Japan's Ministry of Health, Labour and Welfare has approved Bylvay also known as odevixibat for the treatment of pruritus associated with...
► Artikel lesen
19.09.Ipsen Pharma: Bylvay (odevixibat) approved in Japan for rare liver disease PFIC539Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering...
► Artikel lesen
16.09.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 20252
11.09.Ipsen Pharma: Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital2
10.09.Health Canada approves Medison and Ipsen's Bylvay to treat ALGS2
09.09.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 20252
02.09.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 20252
29.08.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 20252
29.08.Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen15
29.08.Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen2
Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1